Trial of Citalopram for the Prevention of Depression
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
With the improved prognosis of human immunodeficiency virus (HIV) infection, end stage liver
disease due to hepatitis C (HCV) now represents a major cause of morbidity and mortality in
people with HIV. Treatment for HCV has become increasingly important as a means of preventing
the consequences of chronic HCV infection. Paradoxically, co-infected patients have low rates
of treatment initiation and completion in large part because they have a high risk of
developing neuropsychiatric symptoms while receiving PEG-interferon (PEG-IFN). There are a
large number of co-infected individuals in Canada who could benefit from HCV therapy if
tolerability could be improved. This trial will address whether prophylactic use of
antidepressants in HIV-HCV infected patients initiating HCV therapy can prevent the
development of neuropsychiatric side effects and thus permit more patients to receive full
treatment for HCV.
Phase:
Phase 3
Details
Lead Sponsor:
Marina Klein
Collaborators:
CIHR Canadian HIV Trials Network Ontario HIV Treatment Network Schering-Plough